References
1. Schunemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines. Ann Intern Med . Oct 6 2015;163(7):548-53. doi:10.7326/M14-1885
2. Institute of Medicine. Clinical Practice Guidelines We Can Trust . The National Academies Press; 2011:290.
3. Murayama A, Kamamoto S, Murata N, et al. Evaluation of financial conflicts of interest and quality of evidence in Japanese gastroenterology clinical practice guidelines. J Gastroenterol Hepatol . Apr 2023;38(4):565-573. doi:10.1111/jgh.16089
4. Mamada H, Murayama A, Kamamoto S, et al. Evaluation of Financial and Nonfinancial Conflicts of Interest and Quality of Evidence Underlying Psoriatic Arthritis Clinical Practice Guidelines: Analysis of Personal Payments From Pharmaceutical Companies and Authors’ Self-Citation Rate in Japan and the United States. Arthritis Care Res (Hoboken) . Jun 2023;75(6):1278-1286. doi:10.1002/acr.25032
5. Murayama A, Yamada K, Yoshida M, et al. Evaluation of Conflicts of Interest among Participants of the Japanese Nephrology Clinical Practice Guideline. Clin J Am Soc Nephrol . Jun 2022;17(6):819-826. doi:10.2215/CJN.14661121
6. Kida F, Murayama A, Saito H, Ozaki A, Shimada Y, Tanimoto T. Pharmaceutical company payments to authors of the Japanese Clinical Practice Guidelines for Hepatitis C treatment. Liver Int . Mar 2021;41(3):464-469. doi:10.1111/liv.14761
7. Harada K, Ozaki A, Saito H, et al. Financial payments made by pharmaceutical companies to the authors of Japanese hematology clinical practice guidelines between 2016 and 2017. Health Policy . Mar 2021;125(3):320-326. doi:10.1016/j.healthpol.2020.12.005
8. Moynihan R, Lai A, Jarvis H, Duggan G, Goodrick S, Beller E, Bero L. Undisclosed financial ties between guideline writers and pharmaceutical companies: a cross-sectional study across 10 disease categories.BMJ Open . Feb 5 2019;9(2):e025864. doi:10.1136/bmjopen-2018-025864
9. Tabatabavakili S, Khan R, Scaffidi MA, Gimpaya N, Lightfoot D, Grover SC. Financial Conflicts of Interest in Clinical Practice Guidelines: A Systematic Review. Mayo Clin Proc Innov Qual Outcomes . Apr 2021;5(2):466-475. doi:10.1016/j.mayocpiqo.2020.09.016
10. Steinbrook R. Guidance for guidelines. N Engl J Med . Jan 25 2007;356(4):331-3. doi:10.1056/NEJMp068282
11. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JP, Guideline Panel Review Working G. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ . Sep 17 2013;347:f5535. doi:10.1136/bmj.f5535
12. Nejstgaard CH, Bero L, Hrobjartsson A, Jorgensen AW, Jorgensen KJ, Le M, Lundh A. Association between conflicts of interest and favourable recommendations in clinical guidelines, advisory committee reports, opinion pieces, and narrative reviews: systematic review. BMJ . Dec 9 2020;371:m4234. doi:10.1136/bmj.m4234
13. Brems JH, Davis AE, Clayton EW. Analysis of conflict of interest policies among organizations producing clinical practice guidelines.PLOS ONE . 2021;16(4):e0249267. doi:10.1371/journal.pone.0249267
14. Ngo-Metzger Q, Moyer V, Grossman D, et al. Conflicts of Interest in Clinical Guidelines: Update of U.S. Preventive Services Task Force Policies and Procedures. Am J Prev Med . Jan 2018;54(1S1):S70-S80. doi:10.1016/j.amepre.2017.06.034
15. Norris SL, Holmer HK, Burda BU, Ogden LA, Fu R. Conflict of interest policies for organizations producing a large number of clinical practice guidelines. PLoS One . 2012;7(5):e37413. doi:10.1371/journal.pone.0037413
16. Ahlawat A, Narayanaswami P. Financial relationships between neurologists and industry: The 2015 Open Payments database.Neurology . May 21 2019;92(21):1006-1013. doi:10.1212/wnl.0000000000007640
17. Messé SR, Smith EE, Getchius TSD, Gronseth GS. American Academy of Neurology replies to Jeanne Lenzer. BMJ : British Medical Journal . 2013;347:f5324. doi:10.1136/bmj.f5324
18. Murayama A, Kida F, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial and Intellectual Conflicts of Interest Among Japanese Clinical Practice Guidelines Authors for Allergic Rhinitis. Otolaryngol Head Neck Surg . May 2022;166(5):869-876. doi:10.1177/01945998211034724
19. Murayama A, Hoshi M, Saito H, et al. Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019. Respiration . 2022;101(12):1088-1098. doi:10.1159/000526576
20. Murayama A, Kamamoto S, Shigeta H, Saito H, Yamashita E, Tanimoto T, Akihiko O. Undisclosed financial conflicts of interest with pharmaceutical companies among the authors of the Esophageal Cancer Practice Guidelines 2017 by the Japan Esophageal Society. Dis Esophagus . Oct 14 2022;35(10)doi:10.1093/dote/doac056
21. Murayama A. Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan.Cureus . Oct 2023;15(10):e46650. doi:10.7759/cureus.46650
22. Yamamoto K, Murayama A, Ozaki A, Saito H, Sawano T, Tanimoto T. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan. Int Urogynecol J . Feb 2021;32(2):443-451. doi:10.1007/s00192-020-04547-3
23. Hashimoto T, Murayama A, Mamada H, Saito H, Tanimoto T, Ozaki A. Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan.Clin Microbiol Infect . Mar 2022;28(3):460-462. doi:10.1016/j.cmi.2021.11.019
24. Murayama A, Ozaki A, Saito H, et al. Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan. PLoS One . 2020;15(10):e0239610. doi:10.1371/journal.pone.0239610
25. Murayama A, Shin N, Higuchi K, Kohli I, Kugo H, Senoo Y. Financial conflicts of interest between infectious diseases clinical practice guideline authors and the pharmaceutical industry in Japan. Infect Dis (Lond) . Feb 1 2024:1-5. doi:10.1080/23744235.2024.2309351
26. Murayama A, Miyazawa K, Kamamoto S, Shigeta H, Kugo H, Higuchi K, Senoo Y. Financial conflicts of interest in Japanese obstetrics and gynaecology clinical practice guidelines. Clinical and Translational Discovery . 2024/02/01 2024;4(1):e273. doi:10.1002/ctd2.273
27. Senoo Y, Saito H, Ozaki A, et al. Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension.Medicine (Baltimore) . Mar 26 2021;100(12):e24816. doi:10.1097/MD.0000000000024816
28. Murayama A. Financial Conflicts of Interest Among the Authors of the Clinical Practice Guidelines for Rheumatoid Arthritis in Japan.Cureus . 2023;15(10)
Table 1. Summary of personal payments to Japanese neurology guideline authors between 2016 and 2020